High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention

Heart

Volumn 97, Issue 12, 2011, Pages 983-990

  Breet, Nicoline J ^a,b   Van Werkum, Jochem W ^a,b   Bouman, Heleen J ^a,b   Kelder, Johannes C ^a,b   Harmsze, Ankie M ^a   Hackeng, Christian M ^a,b   Ten Berg, Jurriën M ^a,b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b St Antonius Center for Platelet Function Research   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; PROSTAGLANDIN E1; PURINERGIC P2Y12 RECEPTOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; STENT THROMBOSIS; THROMBOCYTE AGGLUTINATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; ATHEROSCLEROSIS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STENTS; STROKE; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79956315296     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.220491     Document Type: Article

References (54)

1. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20. (Pubitemid 35340537)
2. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33. (Pubitemid 32772726)
3. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
4. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-6. (Pubitemid 41579802)
5. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420-5. (Pubitemid 44522148)
6. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-50. (Pubitemid 44648629)
7. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-42.
8. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-56.
9. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11. (Pubitemid 351447314)
10. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison between platelet function tests in predicting clinical outcome in patients undergoing coronary stenting. JAMA 2010;303:754-62.
11. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Card 2003;41:961-5. (Pubitemid 36315537)
12. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5. (Pubitemid 34298607)
13. Frelinger AL III, Li Y, Linden MD, et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009;120:2586-96.
14. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000. (Pubitemid 351844676)
15. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33. (Pubitemid 43005160)
16. Gori AM, Marcucci R, Migliorini A, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008;52:734-9.
17. Eshtehardi P, Windecker S, Cook S, et al. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 2010;159:891-8.
18. Ivandic BT, Sausemuth M, Ibrahim H, et al. Dual antiplatelet drug resistance is a risk factor for cardiovascular events after percutaneous coronary intervention. Clin Chem 2009;55:1171-6.
19. Smit JJ, van Werkum JW, Ten Berg JM, et al. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart 2010;96:1815-20.
20. Valgimigli M, Campo G, de CN, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009;119:3215-22.
21. Breet NJ, van Werkum JW, Bouman HJ, et al. High on-aspirin platelet reactivity as measured with aggregation based, COX-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 2010;8:2140-8.
22. Smith SC Jr, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:-166-286.
23. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51. (Pubitemid 46685903)
24. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 1990;21:637-76.
25. Breet NJ, van Werkum JW, Bouman HJ, et al. Both peak and late aggregation are capable of identifying patients at risk for atherothrombotic events. Thromb Haemost 2011;105:197-9.
26. Breet NJ, van Werkum JW, Bouman HJ, et al. Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after PCI. J Thromb Haemost 2010;8:2326-8.
27. Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost 2009;102:719-27.
28. van Werkum JW, Kleibeuker M, Mieremet N, et al. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation? J Thromb Haemost 2007;5:884-6. (Pubitemid 46563599)
29. Pittens CA, Bouman HJ, van Werkum JW, et al. Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests. J Thromb Haemost 2009;7:1929-32.
30. van Werkum JW, Harmsze AM, Elsenberg EH, et al. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008;19:479-88.
31. van Werkum JW, van der Stelt CA, Seesing TH, et al. A head-to-head comparison between the VerifyNow P2Y12-assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective PCI. J Thromb Haemost 2006;4:2516-18. (Pubitemid 44575456)
32. Muir AR, McMullin MF, Patterson C, et al. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 2009;95:1225-9.
33. Gremmel T, Steiner S, Seidinger D, et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 2010;96:186-9.
34. Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost 2010;103:920-5.
35. van Werkum JW, Heestermans AA, Ten Berg JM. Point-of-care devices for monitoring anti-platelet therapy. Thromb Res 2006;118:769-70. (Pubitemid 44647102)
36. Harmsze AM, van Werkum JW, Moral F, et al. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets 2011;22:98-102.
37. Yee DL, Sun CW, Bergeron AL, et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005;106:2723-9. (Pubitemid 41510746)
38. Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-7. (Pubitemid 47532327)
39. Shankar H, Garcia A, Prabhakar J, et al. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006;4:638-47.
40. Bhavaraju K, Kim S, Mao Y, et al. P2Y12 antagonism inhibits serum thromboxane generation: implications for combination therapy with aspirin. J Thromb Haemost 2009;7:Abstract PP-MO-106.
41. May J, Heptinstall S. Thromboxane A2 is a weak platelet agonist requiring coactivation of both the P2Y1 and the P2Y12 receptors for full platelet activation to occur (abstract). J Thromb Haemost 2009;7:Abstract PP-PO-249.
42. van Werkum JW, Ten Berg JM. Platelet reactivity as a risk-factor for stent thrombosis: can this be one of the currently available appropriate methods to determine platelet reactivity? Eurointervention 2008;4(Suppl C):C11-16.
43. Michelson AD, Linden MD, Furman MI, et al. Evidence that pre-existent variability in platelet response to ADP accounts for "clopidogrel resistance". J Thromb Haemost 2007;5:75-81.
44. Cuisset T, Frere C, Quilici J, et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009;123:597-603.
45. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13. (Pubitemid 36736631)
46. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206-11. (Pubitemid 14021923)
47. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-50. (Pubitemid 41612296)
48. van Werkum JW, Hackeng CM, Smit JJ, et al. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol 2008;8:33-55.
49. Bonello L, De Labriolle A, Scheinowitz M, et al. Emergence of the concept of platelet reactivity monitoring of response to thienopyridines. Heart 2009;95:1214-19.
50. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
51. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-6. (Pubitemid 47091403)
52. Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel resistance? Circulation 2009;119:2854-7.
53. Price M. Standard versus high-dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS Trial (abstract). Circulation 2010;122:2215-26.
54. Ten Berg JM, van Werkum JW. Point-of-care platelet function testing in patients undergoing PCI: is it ready for use in clinical practice? Eurointervention 2008;4(Suppl C):C72-4.